

February 10, 2026

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL [Brand Name: Imfinzi] for an additional indication.

Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:- Durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR).

The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL [Imfinzi] in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you,

For AstraZeneca Pharma India Limited

Bhavana Agrawal

Chief Financial Agrawal & Director